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Abstract 34 
The loss of podocyte (PD) molecular phenotype is an important feature of diabetic 35 
podocytopathy. We hypothesized that high glucose (HG) induces dedifferentiation in 36 
differentiated podocytes (DPD) through alterations in APOL1-microRNA (miR) 193a axis. 37 
HG-induced DPDs dedifferentiation manifested in the form of down regulation of WT1 and 38 
upregulation of PAX2 expression.  WT1- silenced DPDs displayed enhanced expression of 39 
PAX2. Immunoprecipitation (IP) of DPD cellular lysates with anti-WT1 antibody revealed 40 
formation of WT1 repressor complexes containing Polycomb group proteins (PcG), EZH2, 41 
Menin, and DNA methyl transferase (DNMT1), whereas, silencing of either WT1 or DNMT1 42 
disrupted this complex with enhanced expression of PAX2. HG-induced DPDs 43 
dedifferentiation was associated with a higher expression of miR193a, whereas, inhibition 44 
of miR193a prevented DPDs dedifferentiation in HG milieu. HG down regulated DPDs 45 
expression of APOL1. MiR193a-overexpressing DPDs displayed down regulation of APOL1 46 
and enhanced expression of dedifferentiating markers; conversely, silencing of miR193a 47 
enhanced the expression of APOL1 and also preserved DPDs phenotype. Moreover, stably 48 
APOL1G0-overexpressing DPDs displayed the enhanced expression of WT1 but 49 
attenuated expression of miR193a; nonetheless, silencing of APOL1 reversed these 50 
effects. Since silencing of APOL1 enhanced miR193a expression as well as 51 
dedifferentiation in DPDs, it appears that down regulation of APOL1 contributed to 52 
dedifferentiation of DPDs through enhanced miR193a expression in HG milieu. Vitamin D 53 
receptor agonist (VDA) down regulated miR193a, upregulated APOL1 expression, and 54 
prevented dedifferentiation of DPDs in HG milieu. These findings suggest that modulation 55 
of the APOL1-miR193a axis carries a potential to preserve DPDs molecular phenotype in 56 
HG milieu. 57 
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Podocytes play a key role in the maintenance of slit diaphragm, a component of the 58 
glomerular filtration barrier (5, 32, 33). Slit diaphragms are composed of several proteins 59 
expressed by podocytes and prevent leakage of plasma proteins (32, 33). An optimal 60 
expression of the slit diaphragm proteins is considered to be an integral part of podocyte 61 
health. Since both parietal epithelial cells (PECs) and podocytes (PDS) are derived from 62 
the same mesenchymal cells during embryogenesis (26, 37), injured adult podocytes go 63 
into dedifferentiation mode- reverting to the expression of PEC markers such as paired 64 
homeo box (PAX)-2 (31, 35, 39). High glucose milieu has been demonstrated to induce 65 
dedifferentiation of PDs as a manifestation of PD injury (2, 16, 18, 37). However, the 66 
mechanisms involved are not clear. 67 
PAX2 is a transcription factor which plays an important role in the development of 68 
kidneys (9-11, 38). In adult kidney, its expression is restricted to glomerular parietal and 69 
tubular epithelial cells (10). However, ectopic PAX2 expression in podocytes is a common 70 
finding in several pathological states including juvenile nephronophthisis (28), focal 71 
segmental glomerulosclerosis (30, 31), collapsing glomerulopathy (7), and diabetic 72 
glomerulosclerosis (2, 25).  Since PAX2 is involved in cellular proliferation (43), this disease 73 
state expression may be an attempt by podocytes to regenerate in adverse milieus. In a 74 
mouse model of podocyte injury, evaluation of PDs dedifferentiation in podocyte reporter 75 
mice demonstrated that PDs expressing PECs markers (PAX2/PAX8) far exceed PECs 76 
expressing PD markers (33). 77 
MicroRNAs (miRs) are small, non-coding RNAs that negatively regulate gene 78 
expression at the post-transcription level (1). By an imperfect sequence complementation, 79 
miRNAs recognize and bind to the 3’-untranslated regions (3’-UTR) of target mRNAs, 80 
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thereby inhibiting mRNA function through degradation, repression of translation, or both. 81 
Recently, miR193a has been demonstrated to induce down regulation of WT1 in podocytes 82 
(25). miR193a is tumor suppressor gene inducing apoptosis in podocytes through 83 
generation of oxidative stress. However, the role of miR193a in high glucose-induced PD 84 
dedifferentiation has not been reported (29). Since WT1 inversely regulate PAX2 85 
expression (8, 34), we hypothesize that high glucose would induce PAX2 expression 86 
through down regulation of WT1 and enhanced PD expression of miR193a. 87 
APOL1 is a minor component of High-Density Lipoprotein (HDL) complex and is 88 
expressed in kidney cells including podocytes, tubular cells, and other cell types (42). It is 89 
predominantly secreted by liver cells and circulates in the plasma (42). The G1 variant is a  90 
missense mutant haplotype (S342G:I384M), encoding two non-synonymous amino acids; 91 
while the G2 variant is a 6 bp in –frame deletion resulting in  loss of two amino acids (N388 92 
and Y389) at the C-terminal helix of APOL1. Approximately 34% of African Americans 93 
(AAs) carry one of the two risk variants and 13% have some combination of both coding 94 
variants (41). Overt expression of APOL1G1 and G2 has been associated with podocyte 95 
injury both in vitro and in vivo studies (3, 15, 23, 24).The trypanolytic activity of circulating 96 
APOL1 (wild-type or G0) has been long appreciated and well characterized, though the 97 
detailed molecular mechanism is not fully resolved (12). The function of APOL1G0 in 98 
podocytes is not clearly understood. We hypothesize that high glucose induces PDs 99 
dedifferentiation through down regulation of APOL1 and upregulation of microRNA (miR) 100 
193a. We further hypothesize that modulation of APOL1-miR193a axis can be used as a 101 
tool to preserve PDs differentiation in high glucose milieu.  102 
 103 
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Material and Methods 104 
Human podocytes 105 
Human podocytes (PDs) were conditionally immortalized by introducing 106 
temperature-sensitive SV40-T antigen by transfection (36). These cells proliferate at the 107 
permissive temperature (33˚C) and enter growth arrest after transfer to the non-permissive 108 
temperature (37˚C). The growth medium contains RPMI 1640 supplemented with 10%fetal 109 
bovine serum (FBS), 1x Pen-Strep, 1 mM L-glutamine and 1x ITS (Invitrogen). 110 
Undifferentiated (UND) PDs were seeded on collagen coated plates and differentiated 111 
through pre-incubation in normal RPMI (containing 11 mM glucose) for 10 days at 37°C 112 
(differentiated podocytes, DPDs). Prior to experimental protocols, DPDs were washed three 113 
times with glucose- and serum-free media. In experimental protocols, DPDs were 114 
incubated in media (glucose- and ITS-free RPMI) containing either normal glucose (5 mM) 115 
or high glucose (30 mM) for 48 h. DNA sequencing of these podocytes revealed APOL1G0 116 
genotype. 117 
Generation of a stable cell lines expressing APOL1G0 and Vector 118 
A stable cell line expressing APOL1G0 was generated by retroviral infection as 119 
described previously (27). Briefly, the open reading frame of APOL1G0 was cloned into the 120 
retroviral vector pBABE carrying resistance to puromycin. To generate retroviral particles, 121 
the viral packaging cell line HEK-GP was co-transfected with the pBABE construct of 122 
interest and the VSV gene. Undifferentiated podocytes (UNDPDs) were infected twice 123 
within 24 h with the viral-containing supernatant of HEK-GP cells. Selection with puromycin 124 
(1 μg/mL) was continued for a week, and expression of the sequence of the APOL1G0 was 125 
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verified. Empty vector pBABE-eGFP was also transduced into UNDPDs to generate the 126 
control cell line. 127 
Transfection of miR193a inhibitor and miR193a expression plasmid 128 
miR193a inhibitor (25 nM; Cat #4464084;Thermofisher, USA), miR193a expression 129 
plasmid (25 nM; Cat #SC400232; Origene), and empty vector  (25 nM; pCMV-MIR; 130 
Origene) were transfected in the cells using Lipofectamine 3000 Transfection Reagent 131 
(Thermo Fisher Scientific, USA) according to the manufacturer's protocol. All miRNA 132 
products were dissolved in nuclease-free water. Briefly, DPDs were transfected at 70 - 80% 133 
confluence in 6 well plates. The Lipofectamine transfection reagent (7.5 µl) and plasmid 134 
DNA were diluted in opti-MEM media (125 µl and 250 µl) (Applied Biosystems, Thermo 135 
Fisher Scientific, USA) followed by addition of P3000 enhancer reagent (10 µl) to diluted 136 
DNA. Diluted DNA (125 µl) was added to diluted Lipofectamine 3000 transfection reagent 137 
(125 µl) in the ratio of 1:1 (v/v) and incubated for 10 min at room temperature (25°C). After 138 
incubation, DNA-lipid complex was added to the cells and kept at 37°C in opti-MEM media 139 
for 48 hrs. Control and transfected cells were harvested for protein and RNA analyses.  140 
Vitamin D Receptor agonist (VDA) treatment 141 
Vitamin D Receptor agonist (VDA; EB1089, 10 nM; Tocris, MN, USA) was used to 142 
modulate the expression of miR193a. VDA (2.2 mM) was initially dissolved in 10% DMSO 143 
(100 µl) and diluted further with sterile PBS buffer (pH 7.2) to achieve final working 144 
concentrations of 10 µM and 1µM. The final concentration of DMSO was 0.1 % in the 145 
vehicle in all the experiments. DPDs in the experimental conditions were treated with VDA 146 
for 48 h and harvested for protein and RNA for further analyses. 147 
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Silencing of APOL1, WT1, and DNMT1 148 
DPDs were transfected with scrambled siRNA (control) or APOL1 siRNA (20 nM; 149 
Santa Cruz), WT1 siRNA (25 nM; Santa Cruz), DNMT1 (25 nM; Santa Cruz) with 150 
Lipofectamine RNAiMAX transfection reagent according to the manufacturer’s protocol 151 
(Thermo Fisher). Briefly, DPDs were transfected at 60-80% confluence in 6 well plates. 152 
Lipofectamine reagent (9 µl) and siRNAs (10 µM, 2-3 µl) were diluted in opti-MEM media 153 
(150 µl) (Thermo Fisher). Then, diluted siRNA (150 µl) was added to diluted Lipofectamine 154 
reagent (150 µl) in 1:1 ratio (v/v) and incubated for 5 min at room temperature (25°C). After 155 
incubation, the siRNA lipid-complex was added to cells and kept at 37°C in opti-MEM 156 
media for 48 hrs. The cells were harvested for protein and RNA analyses. Control and 157 
transfected cells were used under control and experimental conditions. 158 
RNA isolation and qPCR studies 159 
Total RNA was isolated from control and experimental DPDs with TRIzol reagent 160 
(Invitrogen, USA). A 20 µl reaction mix was prepared containing iTaq Universal SYBR 161 
Green reaction mix (2x) (10 µl), iscript reverse transcriptase (0.25 µl), forward and reverse 162 
primers (2 µl), RNA (4 µl), and nuclease free water (3.75 µl). Real-Time PCR was 163 
performed using one-step iTaqTM Universal SYBR Green kit (BIO-RAD, USA) according to 164 
the manufacturer’s instructions using specific primers obtained from Thermo Fisher 165 
Scientific, USA. GAPDH fw 5′ CCC ATC ACC ATC TTC CAG GAG ′3; rev 5′ GTT GTC 166 
ATG GAT GAC CTT GGC ′3, WT1 fw 5′ CGAGAGCGATAACCACACAACG ′3; rev 5′ 167 
GTCTCAGATGCCGACCGTACAA ′3, PAX2fw 5′ GGC TGT GTC AGC AAA ATC CTG ′3; 168 
rev 5′ TCC GGA TGA TTC TGT TGA TGG ′3, APOL1 fw 5′ ATC TCA GCT GAA AGC GGT 169 
GAAC ′3; rev 5′ TGA CTT TGC CCC CTC ATG TAAG ′3. The qPCR conditions were as 170 
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follows: 50°C for 10 min 95°C for 1 min, followed by 40 cycles of 95°C for 15 s, 60°C for 1 171 
min. Quantitative PCR was performed using an ABI Prism 7900HT sequence detection 172 
system and relative quantification of gene expression was calculated using the ΔΔCT 173 
method. Data were expressed as relative mRNA expression in reference to the control, 174 
normalized to the quantity of RNA input by performing measurements on an endogenous 175 
reference gene (GAPDH). 176 
MicroRNA assay 177 
For miRNA quantification, the total RNA was isolated from control and experimental DPDs 178 
with miRVana miRNA isolation kit and 1 µg of RNA was reverse transcribed using miR193a 179 
and U6snRNA specific RT primers to generate first strand cDNA from mRNA using 180 
TaqMan microRNA Reverse Transcription kit (Thermo Fisher Scientific, USA) according to 181 
manufacturer’s instructions. For cDNA, a 15 µl PCR reaction was prepared containing 100 182 
mM dNTP mix (0.15 µl), multiscribe RT enzyme 50 U/µl (1 µl), 10X RT buffer (1.5 µl), 183 
RNase inhibitor 20 U/µl (0.19 µl), nuclease free water (4.16 µl), RNA (5 µl), and primers (3 184 
µl).  The PCR condition was as follows: 16°C for 30 min, 42°C for 30 min, 85°C for 5 min, 185 
and 4°C until stopped. Real-time PCR was performed by using TaqMan-based PCR master 186 
mix and detection primers miR-193a and U6snsubRNA (Thermo Fisher) in ABI-7500, 187 
Applied Biosystems. For real-time PCR a 10 µl reaction mix was prepared containing 188 
TaqMan PCR master mix II (5 µl), cDNA (2 µl), nuclease free water (2 µl), and primer (1 µl). 189 
The qPCR conditions were as follows: 50°C for 2 min 95°C for 10 min, followed by 40 190 
cycles of 95°C for 15 s, 60°C for 1 min. U6 was used as an internal control. Relative 191 
quantification of gene expression was calculated using the ΔΔCT method and the results 192 
were normalized to U6-snuRNA expression. 193 
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Immunofluorescence detection of APOL1 194 
Control and experimental podocytes were fixed and permeabilized with a buffer containing 195 
0.02% Triton X-100 and 4% formaldehyde in PBS. Fixed cells were washed three times in 196 
PBS and blocked in 10% BSA for 60 min at 37˚C. Subsequently, cells were labeled with 197 
anti-APOL1 (Proteintech, IL). DAPI was used for nuclear localization. Control and 198 
experimental cells were examined under immunofluorescence microscope.   199 
Western blotting studies 200 
Western blotting studies were carried out as described previously (4, 17, 22). Briefly, 201 
control and experimental cells were harvested, lysed in RIPA buffer containing 50 mM Tris-202 
Cl (pH 7.5), 150 mMNaCl, 1mM EDTA, 1% NP-40, 0.25% Deoxycholate, 0.1% SDS, 1X 203 
protease inhibitor cocktail (Calbiochem, Cocktail Set I), 1mM PMSF, and 0.2mM sodium 204 
orthovanadate. Protein concentration was measured using Biorad Protein Assay kit. Total 205 
protein lysed extracts (30 g/lane) were loaded on a 10 % polyacrylamide (PAGE) premade 206 
gel (Bio-Rad) and transferred onto PVDF membranes were processed for immunostaining 207 
with primary antibodies against APOL1 (mouse monoclonal, 1:1000, Protein tech), WT1 208 
(rabbit polyclonal, 1:1000, Abcam, MA), PAX2 (rabbit polyclonal,1:800, Abcam), Menin 209 
(mouse monoclonal, 1:1000, Santa Cruz),  DNMT1 (mouse monoclonal, 1:1000, Santa 210 
Cruz), EZH2 (Goat polyclonal, 1:1000, Santa Cruz), RBBP4 (Rabbit polyclonal, 1:1000, 211 
Santa Cruz), and H3K27me3 (rabbit polyclonal, 1:1000, Cell Signaling Technologies, MA), 212 
podocalyxin (rabbit polyclonal, 1:1000, Thermo Fisher) and nephrin (rabbit polyclonal, 213 
1:800, Abcam) followed by treating with horseradish peroxidase labeled appropriate 214 
secondary antibodies. The blots were developed using a chemiluminescence detection kit 215 
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(PIERCE, Rockford, IL) and exposed to X-ray film (Eastman Kodak Co., Rochester, NY). 216 
Equal protein loading and the protein transfer were confirmed by immunoblotting for 217 
determination of actin/GAPDH protein using a polyclonal β-Actin/GAPDH antibody (Santa 218 
Cruz, CA) on the same (stripped) western blots.  219 
Immunoprecipitation (IP) 220 
Lysates from undifferentiated and differentiated PDs were first immunoprecipitated following 221 
the addition of 5 μg of monoclonal antibody to WT1 (Santa Cruz Biotechnology). The 222 
immune complexes were then collected using 25 μl of Protein-A + G sepharose beads (GE 223 
Health Care, Life Science), in RIPA buffer. The IP was carried out at 4ºC, for 4h, on a 224 
rotating platform. Following this, precipitated A/G proteins were pelleted down by 225 
centrifugation at 4,500 rpm for 10 min at 4°C. Next, the protein pellet was washed (3X)  226 
each time with 1 ml of cold RIPA lysis buffer followed by centrifugation each time for 10 227 
minutes at 2,500 rpm in a microfuge. After washings, beads were re-suspended in 100 μl of 228 
lysis buffer to which SDS-PAGE sample buffer (50 μl) was added and samples were boiled 229 
at 100ºC, followed by SDS-PAGE and immunoblotted using specific antibodies as indicated. 230 
Statistical analyses 231 
Statistical comparisons were performed with the program PRISM using the Mann–232 
Whitney U test for nonparametric data and the unpaired t test for parametric data. 233 
A P value<0.05 was accepted as statistically significant. 234 
 235 
 236 
 237 
 238 
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Results  239 
High glucose causes dedifferentiation of podocytes 240 
Dedifferentiation of PDs is characterized by enhanced expression of PAX2 and down 241 
regulation of WT1. To determine the effect of high glucose on PAX2 expression, Proteins 242 
and RNAs were extracted from control and high glucose treated DPDs (n= 3). Protein blots 243 
were probed for PAX2 and re-probed for actin. Gels from three different lysates are 244 
displayed in Fig. 1A (Upper panel). Cumulative densitometric data are shown in bar graphs 245 
(Lower panel, Fig. 1A). High glucose enhanced (P<0.05) expression of PAX2 in DPDs. 246 
cDNAs were amplified with a specific primer for PAX2. Cumulative data on mRNA 247 
expression of PAX2 are shown in Fig. 1C. High glucose also enhanced PAX2 mRNA 248 
expression in DPDs. Protein blots of the same lysate preparations were probed for WT1 249 
and reprobed for actin. Gels from three different lysates are displayed in Fig. 1 B (Upper 250 
panel). Cumulative densitometric data are shown as  a bar graph in the lower panel (Fig. 251 
1B). cDNAs were amplified with a specific primer for WT1. Cumulative data are shown in a 252 
bar graph (Fig.1 D). High glucose down regulated (P<0.05) WT1 mRNA as well as protein 253 
expression in DPDs. These findings suggest that high glucose down regulates transcription 254 
and translation of WT1 but enhances transcription of PAX2 in DPDs.  255 
We examined whether there is a causal relationship between high glucose-induced 256 
down regulation of WT1 and upregulation of PAX2 expression in DPDs. DPDs were 257 
transfected with either scrambled (SCR) or WT1siRNA (n=3). Subsequently, protein blots 258 
were probed for WT1 and reprobed for PAX2 and GAPDH. Gels from three different lysates 259 
are displayed in Fig. 1E. Cumulative densitometric data are shown in Fig. 1F. DPDs 260 
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silenced for WT1 displayed enhanced (P<0.05) PAX2 expression. These findings confirm 261 
that down regulation of WT1 causes upregulation of PAX2 in DPDs. 262 
High glucose induces DPDs dedifferentiation through upregulation of miR193a 263 
Since miR193a is a negative regulator of WT1 in PDs (11), we asked whether high 264 
glucose is down regulating WT1 via up regulation of miR193a. DPDs were incubated in 265 
media containing either normal glucose (control,  5 mM) or high glucose (30 mM) for 48 266 
hours (n=3). RNAs were extracted and assayed for miR193a. As shown in Fig. 2A, high 267 
glucose enhanced expression of miR193a in DPDs. 268 
To determine whether a specific miR193a inhibitor carries the potential to reverse 269 
effect of high glucose milieu, DPDs were incubated in media containing normal glucose (5 270 
mM, control), high glucose (30 mM), empty vector (pCMV-MIR 25 nM) with or without 271 
miR193a inhibitor (25 nM, Applied Biosystems, Thermo Fisher) for 48 hours followed by 272 
RNA extraction. RNAs were assayed for miR193a. High glucose enhanced (P<0.01 the 273 
expression of miR193a in DPDs; however this effect of high glucose was attenuated by 274 
inhibition of miR193a (Fig. 2B).  275 
We hypothesized that if high glucose induced dedifferentiation of DPDs through 276 
upregulation of miR193a, then inhibition of miR193a in high glucose milieu would preserve 277 
DPDs molecular phenotype. DPDs were incubated in media containing either normal 278 
glucose (control, 5 mM), high glucose (30 mM), empty vector (pCMV-MIR, 25 nM)  with or 279 
without a specific inhibitor of miR193a (25 nM) for 48 hours (n=3). Proteins were extracted 280 
and protein blots were probed for WT1 and reprobed for PAX2 and actin. Gels are 281 
displayed in Fig. 2C. Cumulative densitometric data are shown as a bar diagram in Fig. 2D. 282 
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High glucose decreased (P<0.05) DPDs expression of WT1 and enhanced (P<0.05) 283 
expression of PAX2. However, miR193a inhibitor prevented upregulation of PAX2 in high 284 
glucose milieu. These findings confirm that high glucose induces dedifferentiation of DPDs 285 
through upregulation of miR193a.  286 
High glucose down regulates DPDs expression of APOL1 through Upregulation of 287 
miR193a  288 
To determine the dose-response effect of high glucose on APOL1 expression in 289 
DPDs, cells were incubated in media containing variable concentrations of glucose (5, 10, 290 
20, 30, 35 mM) for 48 hours (n=3). Protein blots were probed for APOL1 and reprobed for 291 
GAPDH. Representative gels are displayed in Fig. 3A. Glucose down regulated APOL1 292 
expression in DPDs at higher concentrations (30 mM and above).  293 
To evaluate the APOL1s relationship with dedifferentiation markers, UNDPDs, 294 
DPDs-treated with RPMI containing either conventional glucose (11 mM) or HG (30 mm) 295 
for 48 hours were analyzed for dedifferentiation markers (n=4). Protein blots were probed 296 
for APOL1 and reprobed for WT1, PAX2, and GAPDH. Gels of three different lysates are 297 
displayed in Fig. 3B. Cumulative densitometric data are shown as a bar diagram (Fig. 3C). 298 
DPDs displayed the expression of APOL1 and WT1 but attenuated expression of PAX2; on 299 
the other hand, high glucose inhibited the expression of APOL1 and WT1 but enhanced the 300 
expression PAX2. These findings suggest that down regulation of APOL1 in DPDs is 301 
temporally associated with down regulation of WT1 and upregulation of PAX2 in high 302 
glucose milieu. 303 
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To determine whether miR193a is regulating the expression of APOL1, DPDs were 304 
incubated in media containing either normal glucose (5 mM), high glucose (30 mM), empty 305 
vector (25 nM; pCMV-MIR) with or without miR193a inhibitor (25 nM) for 48 hours (n=3). 306 
Proteins and RNAs were extracted. Protein blots were probed for APOL1 and reprobed for 307 
GAPDH. Gels are displayed in the upper panel of Fig. 3D. Cumulative densitometric data 308 
are shown in bar graphs (Fig. 3E). High glucose down regulated (P<0.05) APOL1 309 
expression in DPDs; however, miR193a inhibitor enhanced (P<0.05) APOL1 expression in 310 
high glucose milieu. RNAs were extracted from the lysates of 3D and cDNAs were 311 
amplified with a specific primer for APOL1. Cumulative data are shown as a bar diagram 312 
(Fig. 3F). High glucose down regulated APOL1 mRNA expression; however, inhibition of 313 
miR193a stimulated APOL1 mRNA expression both in control and high glucose milieus. 314 
These findings suggest that miR193a negatively regulates APOL1 expression in DPDs 315 
under control as well as in high glucose milieus. 316 
DPDs grown on coverslips were incubated in media containing either normal 317 
glucose (C, 5 mM), high glucose (30 mM) with or without a miR193a inhibitor (miR, 25 nM) 318 
for 48 hours (n=3) followed by immuno-labeling for APOL1. Subsequently, cells were 319 
examined under a confocal microscope. Representative fluoromicrographs are shown in 320 
Fig. 3G. High glucose down regulated APOL1 expression (green fluorescence) in DPDs, 321 
however this effect of high glucose was mitigated by inhibition of miR193a. 322 
To determine the effect of overexpression of miR193a on APOL1 expression, DPDs 323 
were transfected with either empty vector (EV) or miR193a plasmid (n=3). Proteins and 324 
RNAs were extracted. Protein blots were probed for WT1, PAX2, APOL1, and re-probed for 325 
GAPDH. Gels from three different lysates are displayed in Fig. 4A. Cumulative 326 
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densitometric data are shown as a bar diagram in Fig. 4B. MiR193a-overexpressing DPDs 327 
showed down regulation of APOL1 and WT1 but upregulation of PAX2. cDNAs were 328 
amplified for APOL1. Cumulative data are shown in a bar diagram (Fig. 4C). DPDs 329 
overexpressing miR193a showed down regulation of APOL1 mRNA. These findings 330 
confirm that miR193a negatively regulates expression of APOL1 in DPDs. 331 
WT1 repressor complex preserves DPDs molecular phenotype 332 
To characterize the molecular phenotypes of undifferentiated (UND) and 333 
differentiated PDs (DPD), protein blots of UNDPDs (0 day incubation) and DPDs (10 days 334 
incubation) were probed for PDs (nephrin, and podocalyxin), PEC (PAX2) markers, APOL1, 335 
components of WT1 repressor complex (RBBP4, EZH2, Menin, H3K27me3, and DNMT1), 336 
and actin. Gels from three different lysates are displayed in Figs. 5A (PD and PEC 337 
markers) and 5B (components of WT1 repressor complex, input for IP data). Cumulative 338 
densitometric data from the lysates of Figs. 5A and 5B are shown as bar diagrams (Figs. 339 
5C and 5D). DPDs (10 days incubation) displayed higher expression of APOL1, nephrin, 340 
and podocalyxin (PDX) but lower expression of PAX2 when compared to undifferentiated 341 
PDs (0 day, Figs. 5A and 5C). Interestingly, DPDs (10 days incubation) displayed 342 
enhanced expression of the components of WT1 repressor complex (Figs. 5B and 5D). 343 
To confirm the composition of WT1 repressor complex, input lysates of UND and 344 
DPD were immunoprecipitated (IP) with the anti-WT1 antibody. IP fractions were probed for 345 
WT1, RBBP4 (Polycomb group protein), EZH2, Menin, H3K27me3, DNMT1, and IgG. Gels 346 
from three different IP fractions are displayed in Fig. 5E. Cumulative densitometric data 347 
from the lysates are shown in bar graphs (Fig 5F). IP fractions of DPDs displayed 348 
enhanced expression of WT1, RBBP4, Menin, EZH2, H3K27me3, and DNMT1 when 349 
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compared to 0 day PDs. These findings confirm that WT1 repressor complex is composed 350 
of WT1, RBBP4, Menin, EZH2, H3K27me3, and DNMT1. 351 
We asked whether the integrity of WT1 repressor complex is critical for the 352 
prevention of dedifferentiation of DPDs. DPDs were transfected with scrambled (SCR), 353 
WT1 siRNA, DNMT1 siRNA or WT1 + DNMT1 siRNAs. After 48 hours, protein blots were 354 
probed for PAX2, WT1, nephrin, podocalyxin (PDX), DNMT1, and reprobed for actin.  Gels 355 
from three different lysates are displayed in Fig. 5G. Cumulative densitometric data are 356 
shown as a bar diagram in Fig. 5H. Lack of either WT1 or DNMT1 enhanced the 357 
expression of PAX2. Interestingly, combined silencing of WT1 and DNMT1 displayed 358 
additive effect on PAX2 expression. These findings suggest that disruption of WT1 359 
repressor complexes de-represses the expression of PAX2. 360 
Role of APOL1 in preservation of DPDs molecular phenotype 361 
To determine the role of APOL1 in the preservation of the DPDs molecular 362 
phenotype, DPDs were transfected with either control (scrambled, SCR) or APOL1 siRNA. 363 
Proteins were extracted from control and transfected cells (n=3).Protein blots were probed 364 
for APOL1 and reprobed for PAX2, WT1, and GAPDH. Gels from three different lysates are 365 
displayed in Fig. 6A. Cumulative densitometric data are shown in a bar diagram (Fig. 6B). 366 
APOL1 silenced DPDs displayed attenuated (P<0.05) expression of WT1 and enhanced 367 
(P<0.05) expression of PAX2 when compared to control and SCR DPDs. These findings 368 
indicate that APOL1 expression is critical for the preservation of DPDs molecular 369 
phenotype.  370 
17 
 
To determine whether APOL1 would be preserving DPDs molecular phenotype 371 
through alterations in miR193a expression, DPDs were transfected with either control 372 
(scrambled, SCR) or APOL1 siRNA. RNAs were extracted from control and transfected 373 
cells (n=3). RNAs were assayed for miR193a. Cumulative data are shown in a bar diagram 374 
(Fig. 6C). 375 
To establish a functional relationship between miR193a and APOL1, DPDs were 376 
transfected with either control (scrambled, SCR) or APOL1 siRNA and incubated in media 377 
with or without miR193a inhibitor (25 nM) for 48 hours (n=3). Protein blots were probed for 378 
APOL1, WT1, PAX2 and GAPDH. Gels from three different lysates are displayed in Fig. 379 
6D. Silencing of APOL1 in DPDs down regulated WT1 and enhanced the expression of 380 
PAX2; however, inhibition of miR193a did not alter this effect of APOL1. These findings 381 
suggest the importance of APOL1 expression to sustain the functionality of APOL1-382 
miR193a axis. 383 
To determine whether, miR193a inhibitor is fully functional in APOL1-silenced PDs, 384 
RNAs were extracted from the lysates of 6D. RNAs were assayed and cumulative data 385 
(n=3) are shown in a bar diagram (Fig. 6E). miR193a inhibitor down regulated PDs 386 
expression of miR193a in control conditions but could not do so in APOL1 silenced-PDs. 387 
These findings suggest that APOL1 is required for the functionality of APOL1-miR193a axis 388 
in DPDs. 389 
APOL1 negatively regulates miR193a expression in DPDs 390 
To confirm a relationship between APOL1 and miR193a, UNDPDs stably expressing vector 391 
and overexpressing APOL1G0 were differentiated (incubation in RPMI containing 11 mM 392 
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glucose for 10 days). APOL1G0-expressing DPDs were transfected with either scrambled 393 
or APOL1 siRNAs (n=6). After 48 hours, proteins and RNAs were extracted. Protein blots 394 
were probed for APOL1 and reprobed for WT1, PAX2 and actin. Gels from three different 395 
lysates are displayed in Fig. 7A. Cumulative densitometric data (n=6) are shown as a bar 396 
diagram (Fig. 7B). DPDs overexpressing APOLG0 displayed enhanced expression of 397 
APOL1 and WT1 but down regulation of PAX2; however, silencing of APOL1 reversed this 398 
APOL1G0.  RNAs were assayed for miR193a and cumulative data are shown as a bar 399 
diagram (Fig. 7C). DPDs overexpressing APOLG0 displayed down regulation of miR93a 400 
expression, however, silencing of APOL1 upregulated the expression of miR193a. These 401 
findings confirm that APOL1 negatively controls the expression of miR193a.  402 
VDR agonist (VDA) preserves DPDs phenotype through modulation of miR193a-403 
APOL1 axis in high glucose milieu 404 
Vitamin D3 has been known to down regulate expression of miR193a in parietal 405 
epithelial cells (20). To determine the effect of VDA on miR193a expression in UNDPDs, 406 
UNDPDs were incubated in  media  containing either vehicle (0.1% DMSO) alone or 407 
different concentrations of VDA (EB1089,  0, 1.0, 10.0, and 100.0 nM) for 48 hours (n=3). 408 
RNAs were extracted and assayed for miR193a. Cumulative data are shown in a bar 409 
diagram (Fig. 8A). VDA down regulated miR193a in UNDPDs in a dose-dependent manner. 410 
To determine the effect of VDA on high glucose-induced modulation of miR193a, 411 
DPDs were incubated in media containing either normal glucose (C, 5 mM), high glucose 412 
(HG, 30 mM), vehicle (0.1% DMSO) with or without VDA (EB1089, 10 nM) for 48 hours 413 
(n=3). RNAs were extracted and assayed for miR193a. Cumulative data are shown as a 414 
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bar diagram (Fig. 8B). High glucose enhanced (P<0.01) expression of miR193a in DPDs. 415 
However, VDA inhibited high glucose-induced upregulation of DPDs expression of 416 
miR193a.  417 
To examine the effect of VDA on high glucose-induced down regulation of APOL1, 418 
DPDs were incubated in media containing either normal glucose (C, 5mM), high glucose 419 
(HG, 30 mM) with or without VDA (EB1089, 10 nM) for 48 hours (n=3). Protein blots were 420 
probed for APOL1 and reprobed for GAPDH. Representative gels are displayed in Fig. 8C. 421 
Cumulative densitometric data are shown in a bar diagram (Fig. 8D). High glucose down 422 
regulated (P<0.05) APOL1 expression in DPDs; however, VDA enhanced APOL1 423 
expression in high glucose milieu. These findings suggest that VDA has potential to 424 
preserve DPDs expression of APOL1 in high glucose milieu.  425 
To evaluate the effect of VDA on high glucose-induced dedifferentiation, DPDs were 426 
incubated in media containing either normal glucose (C, 5mM), vehicle (Veh, 0.1% DMSO 427 
high glucose (HG, 30 mM) with or without VDA (EB1089, 10 nM) for 48 hours (n=3). Protein 428 
blots were probed for WT1, PAX2 and reprobed for GAPDH. Representative gels are 429 
displayed in Fig. 8E. Cumulative densitometric data are shown in a bar diagram (Fig. 8F). 430 
High glucose down regulated (P<0.05) DPDs expression of WT1 but enhanced (P<0.05) 431 
the expression of PAX2. However, VDA enhanced the expression of WT1 under high 432 
glucose milieu. Moreover, VDA down regulated high glucose-induced PAX2 expression in 433 
DPDs. These findings suggest that VDA carries a potential to preserve DPDs molecular 434 
profile in high glucose milieu. 435 
 436 
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Discussion 437 
The present study demonstrated that high glucose (HG) induced dedifferentiation in 438 
DPDs. High glucose enhanced PAX2 expression, a marker of podocyte dedifferentiation, 439 
as a consequence of disruption of WT1 repressor complex. High glucose-induced DPDs 440 
dedifferentiation was associated with a higher expression of miR193a and inhibition of 441 
miR193a prevented DPDs dedifferentiation. DPDs overexpressing miR193a displayed 442 
down regulation of APOL1 and enhanced expression of dedifferentiating markers; 443 
conversely, silencing of miR193a enhanced the expression of APOL1 and also preserved 444 
DPDs phenotype. Interestingly, high glucose also attenuated DPDs expression of APOL1. 445 
Moreover, stably APOL1G0-overexpressing DPDs displayed the enhanced expression of 446 
WT1 but attenuated expression of miR193a; nonetheless, silencing of APOL1 reversed 447 
these effects. Since silencing of APOL1 enhanced miR193a expression as well as 448 
dedifferentiation in DPDs, it appears that down regulation of APOL1 contributed to 449 
enhanced miR193a expression in HG milieu. Vitamin D receptor agonist (VDA) down 450 
regulated miR193a, upregulated APOL1 expression, and prevented dedifferentiation of 451 
DPDs in HG milieu.  These findings suggest a novel role of APOL1 in the preservation of 452 
molecular phenotype of DPDs in high glucose milieu.  453 
Expression of parietal epithelial proteins such as Claudin 1 and PAX2 in the 454 
glomerular capillary tufts in diabetic nephropathy could be a consequence of the 455 
replacement of PDs by PECs or PDs reversal to PECs phenotype. Chen et al 456 
demonstrated that high glucose milieu enhanced PAX2 gene expression in mouse 457 
embryonic mesenchymal epithelial cells and kidney explants (6). In an experimental model 458 
of podocyte reporter mice, podocyte injury stimulated expression of PAX2 (34). Therefore, 459 
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expression of PAX2 by glomerular capillary epithelial cells may not be able to predict their 460 
lineage. 461 
WT1 has been reported to regulate PAX2 expression negatively through the 462 
formation of a repressor complex (44).WT1 repressor complex containing PcG proteins, 463 
EZH2, and Menin binds at PAX2 gene and has been demonstrated to decrease 464 
transcription of PAX2 (40, 44). In the present study, high glucose down regulated WT1 and 465 
decreased the transcription of PAX2 in DPDs. WT1 bound IP fraction revealed the 466 
presence of PcG protein, EZH2, Menin and DNMT1. Silencing of WT1 or DNMT1 disrupted 467 
the repressor complex and upregulated PAX2 expression in DPDs. These findings suggest 468 
that high glucose-induced down regulation of WT1 and enhanced PAX2 expression 469 
occurred through disruption of WT1 repressor complex. We have displayed proposed 470 
composition of WT1 repressor complex on PAX2 in Fig.  9A. However, these observations 471 
need to be confirmed in vivo studies.  472 
MicroRNA193a has been demonstrated to regulate WT1 transcription inversely in 473 
podocytes (14). miR193a transgenic mice displayed loss of WT1 by podocytes and 474 
developed focal glomerular sclerosis (14). Notably, dedifferentiation of PDs in the form of 475 
PAX2 expression was not studied in this model. In the present study, high glucose 476 
enhanced expression of miR193a and down regulated WT1 expression in the podocytes.  477 
Inhibition of miR193a caused upregulation of podocyte WT1 expression in high glucose 478 
milieu, suggesting an inverse relationship between miR193a and WT1 in high glucose 479 
milieu. Moreover, inhibition of miR193a upregulated PD expression of WT1 and down 480 
regulated PAX2 expression in high glucose milieu. These findings suggest that modulation 481 
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of miR193a could be used as a therapeutic strategy to preserve podocyte molecular 482 
integrity in high glucose milieu. 483 
In the present study, high glucose-induced upregulation of miR193a displayed a 484 
temporal relationship with down regulation of APOL1 expression in PDs. On the other 485 
hand, APOL1-silenced PDs displayed upregulation of miR193a and over-expressing 486 
APOL1-PDs showed down regulation of miR193a expression. These findings suggest a 487 
negative feedback relationship between APOL1 and miR193a in PDs. As noted below, this 488 
miR193a-mediated down regulation of APOL1 in high glucose milieu could provide an 489 
explanation for the low or absence of any association of APOL1 renal risk variants with 490 
diabetic kidney disease (13). On the other hand, down regulation of APOL1 was associated 491 
with dedifferentiation of DPDs both in high glucose milieu as well as under control 492 
conditions; while upregulation of APOL1 provided protection against dedifferentiation of 493 
podocytes in high glucose milieu. Therefore, enhanced APOL1 expression could be 494 
considered with caution as a strategy to preserve podocyte phenotype in high glucose or 495 
related adverse milieus. However, in the absence of such adverse milieus it is considered 496 
that APOL1 expression may be dispensable to kidney health (19). 497 
Since LPS, TNF-α, HIV and IFN-γ have been reported to enhance expression of 498 
APOL1 in podocytes (23, 24, 27), these agents could be used to prevent down regulation of 499 
APOL1 in high glucose milieu. However, these agents are phlogogenic de novo, and would 500 
not be suitable in chronic kidney disease-carrying pre-existing inflammatory milieu. In our 501 
study, we observed that VDA not only down regulated miR193a but also enhanced PD 502 
expression of APOL1 in high glucose milieu. Therefore, VDA could be used to provide 503 
protection against dedifferentiation in high glucose milieu through enhanced PD expression 504 
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of APOL1. However, using VDA for increasing APOL1 in high glucose milieu would be 505 
detrimental for PDs health if the host carries APOL1 risk alleles (3, 15, 23, 24). Therefore, it 506 
would be mandatory to characterize the genetic profile of APOL1 before using VDA as a 507 
therapeutic strategy to preserve PDs molecular phenotype in high glucose milieu. 508 
Genetic epidemiology indicated that African Americans (AAs) carrying APOL1 risk 509 
alleles (G1 and G2) are prone to develop chronic kidney diseases at higher rates with few 510 
exceptions such as diabetic nephropathy when compared to European Americans (13, 21, 511 
41). In the present study, high glucose milieu down regulated expression of APOL1 in 512 
podocytes; therefore, high glucose milieu would also down regulate podocyte expression of 513 
APOL1 risk alleles in Africans Americans carrying APOL1 risk alleles. Since enhanced 514 
expression of APOL1 risk alleles has been reported to be cytotoxic to podocytes, down 515 
regulation of APOL1 risk alleles in high glucose milieu is unlikely to modulate net outcome.  516 
Therefore, our data are consistent with the epidemiologic observations (13).  517 
We conclude that high glucose-induced up regulation of miR193a stimulated 518 
attenuated expression of APOL1 manifesting in the form of DPDs dedifferentiation (Fig. 519 
9B). This effect of high glucose could be prevented by VDA through the reversal of APOL1-520 
miR193 axis alterations.  521 
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Figure legends 687 
Fig. 1.High glucose causes dedifferentiation of podocytes 688 
A. Differentiated podocytes (pre-incubated in RPMI 1640 media containing glucose [11 689 
mM] at 37°C; DPDs) were incubated in media containing normal glucose (C, 5 mM) 690 
or high glucose (HG, 30 mM) for 48 hours  (n=3). Proteins were extracted. Protein 691 
blots were probed for PAX2 and re-probed for actin. Gels from three different lysates 692 
are displayed (Upper panel). Cumulative densitometric data are shown in bar graphs 693 
(Lower panel). *P<0.05 compared with C.  694 
B. Protein blots from the lysate preparations of 1A were probed for WT1 and re-probed 695 
for actin. Gels from three different lysates are displayed. Cumulative data are shown 696 
in a bar diagram. *P<0.05 compared with C.  697 
C. RNAs were extracted from the lysates of 1A. cDNAs were amplified with a specific 698 
primer for PAX2. Cumulative data on mRNA expression of PAX2 are shown. 699 
*P<0.05 compared with C.  700 
D. RNAs were extracted from the lysates of 1A. cDNAs were amplified with a specific 701 
primer for WT1. Cumulative data on WT1 mRNA expression are shown. *P<0.05 702 
compared with C.  703 
E. DPDs were transfected with scrambled (SCR, 25 nM) or WT1 (25 nM) siRNAs with 704 
Lipofectamine RNAiMAX transfection reagent according to manufacturer’s protocol 705 
and left in opti-MEMmedia for 48 hrs (n=3). Subsequently, proteins were extracted 706 
and protein blots from control and transfected cells were probed for WT1 and 707 
reprobed for PAX2 and GAPDH. Gels from three different lysates are displayed.  708 
F.  Cumulative densitometric data from the gels of 1E are shown in a bar diagram.  709 
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 *<0.05 compared with respective C and SCR.  710 
Fig. 2.High glucose induces PDs dedifferentiation through upregulation of mIR193a 711 
A. DPDs were incubated in media containing either normal glucose (control,  5 mM) or 712 
high glucose (30 mM) for 48 hours (n=4). RNAs were extracted and assayed for 713 
miR193a. Cumulative data are shown in a bar diagram. *P<0.05 compared with C. 714 
B. DPDs were incubated in media containing either normal glucose (5 mM, control), 715 
high glucose (30 mM), empty vector (25 nM; pCMV-MIR; using lipofectamine as a 716 
carrier) with or without miR193a inhibitor (25 nM, plasmid-based inhibitor using 717 
lipofectamine as a carrier)   for 48 hours (n=3). RNAs were extracted and assayed 718 
for miR193a. **P<0.01 with other variables. 719 
C. DPDs were incubated in media containing either normal glucose (control, 5 mM), 720 
high glucose (30 mM) empty vector (25 nM) with/without a specific inhibitor of 721 
miR193a (25 nM) (n=3). After 48 hours, proteins were extracted. Protein blots were 722 
probed for WT1 and re-probed for PAX2 and actin. Gels are displayed.  723 
D. Cumulative densitometric data from the protein blots of 2C. *P<0.05 compared to 724 
other WT1/PAX2 variables; aP<0.05 compared to respective C.  725 
Fig. 3.High glucose Down regulates DPD expression of APOL1 through Upregulation 726 
of miR193a  727 
A. DPDs were incubated in media containing different concentrations of glucose (5, 728 
10, 20, 30, 35) for 48 hours (n=3). Protein blots were probed for APOL1 and re-729 
probed for GAPDH. Representative gels are displayed.  730 
B. DPDs were incubated in media containing either conventional glucose (11 mM) 731 
or HG (30 mm) for 48 hours. Proteins were extracted from UNDPDs and 732 
33 
 
experimental DPDs (n=4). Protein blots were probed for APOL1 and reprobed for 733 
WT1, PAX2, and GAPDH. Gels of three different lysates are displayed.  734 
C. Cumulative densitometric data of protein blots of 3B are shown in a bar diagram.  735 
*P<0.05 compared to respective UNDPD and DPD/HG; **P<0.01 compared to 736 
respective UNDPD and DPD/HG. 737 
D. DPDs were incubated in media containing either normal glucose (5 mM), high 738 
glucose (30 mM), empty vector (25 nM) with or without miR193a inhibitor (25 nm, 739 
miR-Inh) for 48 hours (n=3). Proteins were extracted. Protein blots were probed 740 
for APOL1 and re-probed for GAPDH. Gels are displayed. 741 
E. Cumulative densitometric data are shown in bar graphs. *<0.05 compared with C 742 
and EV; aP<0.05 compared with HG alone.  743 
F. RNAs were extracted from the lysate preparations of 3D and cDNAs were 744 
amplified for APOL1 mRNA. Cumulative data are shown in a bar diagram. 745 
*P<0.05 compared with respective C and EV; **P<0.01 compared with C, EV, 746 
and HG alone; ***P<0.001 compared with C, EV, and HG alone; aP<0.05 747 
compared with miR-Inh alone.  748 
G. DPDs grown on coverslips were incubated in media containing either normal 749 
glucose (C), high glucose with or without a miR193a inhibitor (miR, 25 nM) for 48 750 
hours (n=3) followed by immuno-labeling for APOL1. Subsequently, cells were 751 
examined under a confocal microscope. Representative fluoromicrographs are 752 
shown.  753 
Fig. 4. Overexpression of miR193a down regulates APOL1 754 
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A. DPDs were transfected with either empty vector (EV) or miR193a plasmid (n=3). 755 
Proteins were extracted. Protein blots were probed for WT1, PAX2, APOL1, and 756 
re-probed for GAPDH. Gels from three different lysates are displayed.  757 
B. Cumulative densitometric data from the lysates of 4A.*P<0.05 compared to 758 
Control and EV; **P<0.01 compared to Control and EV. 759 
C. RNAs were extracted from the lysates of 4A. cDNAs were amplified with a 760 
specific primer for APOL1. *P<0.05 compared with other variables.  761 
Fig. 5. WT1 repressor complex preserves DPDs molecular phenotype 762 
A. Protein blots of UNDPDs (0 day incubation) and DPDs (10 day incubation) were 763 
probed for PDs (nephrin, WT1, and podocalyxin) and PEC (PAX2) markers, 764 
APOL1, and actin. Gels from three different lysates are displayed.  765 
B. Protein blots from 5A were reprobed for the components of WT1 repressor 766 
complex. Gels from three different lysates are displaced. 767 
C. Cumulative densitometric data from the lysates of 5A are shown as a bar 768 
diagram. *P<0.05 compared to respective 0 day. 769 
D. Cumulative densitometric data from the lysates of 5B are shown as a bar 770 
diagram. *P<0.05 compared to respective 0 day. 771 
E. Lysates from 5A were immunoprecipitated (IP) with the anti-WT1 antibody. IP 772 
fractions were probed for WT1, RBBP4 (Polycomb group protein), Menin, 773 
H3K27me3, DNMT1, and IgG. Gels from three different IP fractions are 774 
displayed.  775 
F. Cumulative densitometric data from the lysates of 5E are shown as bar graphs. 776 
*P<0.05 compared with respective 0 day. 777 
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G. DPDs were transfected with either scrambled (SCR), WT1 siRNA (25 nM), 778 
DNMT1 (25 nM), WT1+DNMT1 siRNAs with Lipofectamine RNAiMAX 779 
transfection reagent according to manufacturer’s protocol and left in opti-780 
MEMmedia for 48 hrs (in WT1 + DNMT1 experiments, cells were exposed to WT1 781 
siRNA for 48 hours and DNMT1 siRNA for 24 hours). Subsequently, proteins were 782 
extracted. Protein blots were probed for PAX2, WT1, nephrin, podocalyxin 783 
(PDX), DNMT1 and reprobed for actin.  Gels from three different lysates are 784 
displayed. 785 
H. Cumulative densitometric data from the lysates of 5G are shown as a bar 786 
diagram. *P<0.05 compared to C, SCR, and siRNADNMT1 in PAX2 variables; 787 
**P<0.01 compared to C, SCR, and siRNADNMT1 in PAX2 variables; aP<0.05 788 
compared with C and SCR in Nephrin variables; bP<0.0.05 compared with C and 789 
SCR in PDX variables; cP<0.01 compared C and SCR in WT1 variables; dP<0.01 790 
compared with siRNADNMT1, C and SCR in DNMT1 variables. 791 
Fig. 6.Role of APOL1 in preservation of DPDs molecular phenotype 792 
A. DPDs were transfected with either control (scrambled, SCR) or APOL1 siRNA. 793 
Proteins were extracted from control and transfected cells (n=3).Protein blots were 794 
probed for APOL1 and re-probed for PAX2, WT1, and GAPDH. Gels from three 795 
different lysates are displayed.  796 
B. Cumulative densitometric data of protein blots displayed in 6A. *P<0.05 compared 797 
with respective APOL1, WT1, and PAX2 in control and SCR variables.  798 
C. DPDs were transfected with either control (scrambled, SCR) or APOL1 siRNA. 799 
RNAs were extracted from control and transfected cells (n=3) and assayed for 800 
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miR193a. Cumulative data are shown in a bar diagram.**P<0.01 compared with 801 
other variables.  802 
D. DPDs were transfected with either control (scrambled, SCR) or APOL1siRNA and 803 
incubated in media with or without miR193a inhibitor for 48 hours (n=3). Protein blots 804 
were probed for APOL1, WT1, PAX2 and GAPDH. Gels from three different lysates 805 
are displayed. 806 
E. RNAs were extracted from the lysate preparations of 6D and assayed for miR193a. 807 
Cumulative data are shown in a bar diagram. *P<0.05 compared with control and 808 
SCR; **P<0.01 compared with control, miR193a inh alone, and SCR; aP<0.05 with 809 
all other variables. 810 
7. APOL1 negatively regulates miR193a expression in DPDs 811 
A. UNDPDs stably expressing vector and overexpressing APOL1G0 were incubated in 812 
RPMI containing 11 mM glucose and 10% serum for 10 days at 37οC. APOL1G0-813 
expressing DPDs were transfected with either scrambled or APOL1 siRNAs (n=6). 814 
After 48 hours, proteins were extracted from control (vector) and siRNA-transfected 815 
cells. Protein blots were probed for APOL1 and reprobed for WT1, PAX2 and actin. 816 
Representative gels from three different lysates are displayed.  817 
B. Cumulative densitometric data (n=6) from the protein blots of 7A are shown in a bar 818 
diagram. *P<0.05 compared with V and G0 APOL1 siRNA in WT1  and all other 819 
variables in PAX2 proteins; **P<0.01 compared with V and G0 APOL1 siRNA in 820 
APOL1 protein.  821 
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C. RNAs were extracted from the lysates of the protocol 7A. RNAs were assayed for 822 
miR193a and cumulative data are shown in a bar diagram. *P<0.05 compared with 823 
vector; **P<0.01 compared with vector; ***P<0.001 compared with G0 and G0/SCR. 824 
Fig. 8. VDR agonist (VDA) preserves DPDs phenotype through modulation of 825 
miR193a-APOL1 axis in high glucose milieu 826 
A. UNDPDs were incubated in media containing either vehicle (0.1% DMSO) alone or 827 
different concentrations of VDA (EB1089, 0, 1, 10, and 100 nM) for 48 hours (n=3). 828 
RNAs were extracted and assayed for miR193a. Cumulative data are shown in a bar 829 
diagram. *P<0.05 compared with vehicle (VDA, 0 nM), VDA, 0 and1.0 nM;**P<0.01 830 
compared with vehicle (VDA, 0 nM), VDA, 0 and 1.0 nM; aP<0.05 compared with 831 
VDA, 10 nM. 832 
B. DPDs were incubated in media containing normal glucose (C, 5mM), high glucose 833 
(HG, 30 mM), vehicle (0.1% DMSO with or without VDA (EB1089, 10 nM) for 48 834 
hours (n=3). RNAs were extracted and assayed for miR193a. Cumulative data are 835 
shown in a bar diagram. **P<0.01 compared with other variables. 836 
C. DPDs were incubated in media containing either normal glucose (C, 5mM), high 837 
glucose (HG, 30 mM) with or without VDA (EB1089, 10 nM) for 48 hours (n=3). 838 
Protein blots were probed for APOL1 and re-probed for GAPDH. Representative 839 
gels are displayed. 840 
D. Cumulative densitometric data from the lysates of 8C are shown in a bar diagram. 841 
*<0.05 compared to C; aP<0.05 compared to HG alone.  842 
E. DPDs were incubated in media containing either normal glucose (C, 5mM), vehicle 843 
(Veh, 0.1% DMSO, high glucose (HG, 30 mM) with or without VDA (EB1089, 10 nM) 844 
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for 48 hours (n=3). Protein blots were probed for WT1, PAX2 and re-probed for 845 
GAPDH. Representative gels are displayed.  846 
F. Cumulative densitometric data from the protein blots of 8E are shown in a bar 847 
diagram. *P<0.05 compared with respective all other variables.  848 
 849 
Fig. 9. Proposed mechanistic schemes 850 
A. Composition of WT1 repressor complex is shown in a cartoon. WT1 repressor 851 
complex binding to PAX2 promoter represses its transcription. Disruption of this 852 
complex would de-repress the expression of PAX2. 853 
B. High glucose enhanced the expression of miR193a, which led to down regulation of 854 
APOL1 expression in DPDs. These alterations in miR193a-APOL1 axis induced 855 
DPDs dedifferentiation. VDA provided protection against this effect of high glucose 856 
through the reversal of miR193a-APOL1 axis alterations. 857 
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